Status:
COMPLETED
NAD Therapy for Improving Memory and Brain Blood Flow in Older Adults With Mild Cognitive Impairment
Lead Sponsor:
University of Delaware
Collaborating Sponsors:
National Institute on Aging (NIA)
Conditions:
Mild Cognitive Impairment
Eligibility:
All Genders
60-90 years
Phase:
PHASE1
PHASE2
Brief Summary
This study will provide insight into whether a nutritional supplement, nicotinamide riboside (NR), improves memory and brain blood flow in older adults with low memory abilities. Overall, this project...
Eligibility Criteria
Inclusion
- Inclusion Criteria
- Cognitive function scores consistent with amnestic mild cognitive impairment based on pre-screening evaluation;
- age 60-90 years;
- MMSE score \>24 at time of initial consent;
- Exclusion Criteria
- blood chemistries indicative of abnormal renal, liver, thyroid and adrenal function; estimated glomerular filtration rate using the MDRD prediction equation must be \>30 ml/min/1.73 m2;
- any clinically significant abnormal blood chemistry values as determined by the research nurse or NMPCC nurse practitioner;
- major psychiatric disorder (e.g. schizophrenia, bipolar disorder, major depression within past two years);
- neurological or autoimmune conditions affecting cognition (e.g. Parkinson's disease, epilepsy, multiple sclerosis, mild or severe traumatic brain injury, large vessel infarct);
- concussion within last 2 years and ≥ 3 lifetime concussions;
- current systemic medical illnesses (e.g. cardiovascular disease, cancer, renal failure);
- prior history of any type of cancer;
- substance abuse or dependence (DSM-V criteria);
- current use of medications used to treat dementia (e.g., anticholinesterase drugs) or other drugs likely to affect cognition (e.g., anticholinergic drugs, long-acting benzodiazepines);
- claustrophobia, metal implants, pacemaker or other factors affecting feasibility and/or safety of MRI scanning\*;
- current smoking (including marijuana) within the past 3 months;
- hospitalization as a result of COVID-19
Exclusion
Key Trial Info
Start Date :
March 20 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 22 2024
Estimated Enrollment :
64 Patients enrolled
Trial Details
Trial ID
NCT03482167
Start Date
March 20 2019
End Date
January 22 2024
Last Update
April 4 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Neurovascular Aging Laboratory
Newark, Delaware, United States, 19713